Correlation Between Large Capitalization and Health Biotchnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Large Capitalization and Health Biotchnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Large Capitalization and Health Biotchnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Large Capitalization Growth and Health Biotchnology Portfolio, you can compare the effects of market volatilities on Large Capitalization and Health Biotchnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Large Capitalization with a short position of Health Biotchnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Large Capitalization and Health Biotchnology.

Diversification Opportunities for Large Capitalization and Health Biotchnology

-0.55
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Large and Health is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding Large Capitalization Growth and Health Biotchnology Portfolio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Health Biotchnology and Large Capitalization is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Large Capitalization Growth are associated (or correlated) with Health Biotchnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Health Biotchnology has no effect on the direction of Large Capitalization i.e., Large Capitalization and Health Biotchnology go up and down completely randomly.

Pair Corralation between Large Capitalization and Health Biotchnology

Assuming the 90 days horizon Large Capitalization Growth is expected to generate 1.21 times more return on investment than Health Biotchnology. However, Large Capitalization is 1.21 times more volatile than Health Biotchnology Portfolio. It trades about 0.28 of its potential returns per unit of risk. Health Biotchnology Portfolio is currently generating about -0.1 per unit of risk. If you would invest  3,053  in Large Capitalization Growth on September 2, 2024 and sell it today you would earn a total of  546.00  from holding Large Capitalization Growth or generate 17.88% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Large Capitalization Growth  vs.  Health Biotchnology Portfolio

 Performance 
       Timeline  
Large Capitalization 

Risk-Adjusted Performance

21 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Large Capitalization Growth are ranked lower than 21 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly weak technical and fundamental indicators, Large Capitalization showed solid returns over the last few months and may actually be approaching a breakup point.
Health Biotchnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Health Biotchnology Portfolio has generated negative risk-adjusted returns adding no value to fund investors. In spite of fairly strong forward indicators, Health Biotchnology is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Large Capitalization and Health Biotchnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Large Capitalization and Health Biotchnology

The main advantage of trading using opposite Large Capitalization and Health Biotchnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Large Capitalization position performs unexpectedly, Health Biotchnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Health Biotchnology will offset losses from the drop in Health Biotchnology's long position.
The idea behind Large Capitalization Growth and Health Biotchnology Portfolio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Complementary Tools

Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets